ABTL0812 enhances antitumor effect of paclitaxel and reverts chemoresistance in triple‐negative breast cancer models

Emma Polonio-Alcalá; Sònia Solé-Sánchez; Pau Muñoz-Guardiola; Elisabet Megías-Roda; Héctor Perez-Montoyo; Marc Yeste-Velasco; Jose Alfón; Jose Miguel Lizcano; Carles Domènech; Santiago Ruiz-Martínez; Teresa Puig

doi:10.1002/cac2.12282

ABTL0812 enhances antitumor effect of paclitaxel and reverts chemoresistance in triple‐negative breast cancer models

Emma Polonio-Alcalá, Sònia Solé-Sánchez, Pau Muñoz-Guardiola, Elisabet Megías-Roda, Héctor Perez-Montoyo, Marc Yeste-Velasco, Jose Alfón, Jose Miguel Lizcano, Carles Domènech, Santiago Ruiz-Martínez, Teresa Puig

Producció científica: Contribució a revista › Article › Recerca › Avaluat per experts

3 Cites (Scopus)

Idioma original	Anglès
Número d’article	12282
Pàgines (de-a)	567-571
Nombre de pàgines	5
Revista	Cancer Communications
Volum	42
Número	6
Data online anticipada	16 de març 2022
DOIs	https://doi.org/10.1002/cac2.12282
Estat de la publicació	Publicada - 1 de juny 2022

SDG de les Nacions Unides

Aquest resultat contribueix als següents objectius de desenvolupament sostenible.

Accés al document

10.1002/cac2.12282

Altres arxius i enllaços

Com citar-ho

Polonio-Alcalá, E., Solé-Sánchez, S., Muñoz-Guardiola, P., Megías-Roda, E., Perez-Montoyo, H., Yeste-Velasco, M., Alfón, J., Lizcano, J. M., Domènech, C., Ruiz-Martínez, S., & Puig, T. (2022). ABTL0812 enhances antitumor effect of paclitaxel and reverts chemoresistance in triple‐negative breast cancer models. Cancer Communications, 42(6), 567-571. Article 12282. https://doi.org/10.1002/cac2.12282

@article{f95f485384c94d9cada1c6d3142f85ee,

title = "ABTL0812 enhances antitumor effect of paclitaxel and reverts chemoresistance in triple‐negative breast cancer models",

keywords = "ABTL0812, Autophagy, Breast Cancer, Chemoresistance, TRIB3, Targeted Therapy",

author = "Emma Polonio-Alcal{\'a} and S{\`o}nia Sol{\'e}-S{\'a}nchez and Pau Mu{\~n}oz-Guardiola and Elisabet Meg{\'i}as-Roda and H{\'e}ctor Perez-Montoyo and Marc Yeste-Velasco and Jose Alf{\'o}n and Lizcano, {Jose Miguel} and Carles Dom{\`e}nech and Santiago Ruiz-Mart{\'i}nez and Teresa Puig",

note = "Funding Information: This research was funded by the Spanish Ministry of Economy and Competitiveness (MINECO) (RETOS: RTC‐2014‐2589‐1; EMPLEA: EMP‐TU‐2015‐4576), the Catalan Government (2017SGR00385), and Instituto de Salud Carlos III and co‐funded by European Union (ERDF/ESF, “A way to make Europe”/“Investing in your future”) (PI19/00372). This work was partially supported by Fundaci{\'o}n Ram{\'o}n Areces and Fundaci{\'o} Oncolliga and RadikalSwim (OncoSwim).",

year = "2022",

month = jun,

day = "1",

doi = "10.1002/cac2.12282",

language = "English",

volume = "42",

pages = "567--571",

number = "6",

}

Polonio-Alcalá, E, Solé-Sánchez, S, Muñoz-Guardiola, P, Megías-Roda, E, Perez-Montoyo, H, Yeste-Velasco, M, Alfón, J, Lizcano, JM, Domènech, C, Ruiz-Martínez, S & Puig, T 2022, 'ABTL0812 enhances antitumor effect of paclitaxel and reverts chemoresistance in triple‐negative breast cancer models', Cancer Communications, vol. 42, núm. 6, 12282, pàg. 567-571. https://doi.org/10.1002/cac2.12282

ABTL0812 enhances antitumor effect of paclitaxel and reverts chemoresistance in triple‐negative breast cancer models. / Polonio-Alcalá, Emma; Solé-Sánchez, Sònia; Muñoz-Guardiola, Pau et al.
In: Cancer Communications, Vol. 42, Núm. 6, 12282, 01.06.2022, pàg. 567-571.

Producció científica: Contribució a revista › Article › Recerca › Avaluat per experts

TY - JOUR

T1 - ABTL0812 enhances antitumor effect of paclitaxel and reverts chemoresistance in triple‐negative breast cancer models

AU - Polonio-Alcalá, Emma

AU - Solé-Sánchez, Sònia

AU - Muñoz-Guardiola, Pau

AU - Megías-Roda, Elisabet

AU - Perez-Montoyo, Héctor

AU - Yeste-Velasco, Marc

AU - Alfón, Jose

AU - Lizcano, Jose Miguel

AU - Domènech, Carles

AU - Ruiz-Martínez, Santiago

AU - Puig, Teresa

N1 - Funding Information: This research was funded by the Spanish Ministry of Economy and Competitiveness (MINECO) (RETOS: RTC‐2014‐2589‐1; EMPLEA: EMP‐TU‐2015‐4576), the Catalan Government (2017SGR00385), and Instituto de Salud Carlos III and co‐funded by European Union (ERDF/ESF, “A way to make Europe”/“Investing in your future”) (PI19/00372). This work was partially supported by Fundación Ramón Areces and Fundació Oncolliga and RadikalSwim (OncoSwim).

PY - 2022/6/1

Y1 - 2022/6/1

KW - ABTL0812

KW - Autophagy

KW - Breast Cancer

KW - Chemoresistance

KW - TRIB3

KW - Targeted Therapy

UR - http://www.scopus.com/inward/record.url?scp=85126319747&partnerID=8YFLogxK

UR - https://www.mendeley.com/catalogue/c1c02849-5b62-3110-a799-0b74328c3dd0/

U2 - 10.1002/cac2.12282

DO - 10.1002/cac2.12282

M3 - Article

C2 - 35293148

SN - 1000-467X

VL - 42

SP - 567

EP - 571

JO - Cancer Communications

JF - Cancer Communications

IS - 6

M1 - 12282

ER -